An observational study in Traumatic Brain Injury, sponsored by Banyan Biomarkers, Inc. Completed at 10 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-16.
Sponsored by Banyan Biomarkers, Inc · Observational
The primary objective of the clinical trial is to evaluate the effect of time on levels of Ubiquitin C-terminal Hydrolase-L1 (UCH-L1) and Glial Fibrillary Acidic Protein (GFAP) biomarker levels in a population of head injured subjects over the age of 18 presenting acutely with a Glasgow Coma Scale score 13-15 as well as in a group of uninjured control subjects.
2,113 studies on the registry are indexed under Brain Injuries; 385 are open to participants now.
This study's enrollment of 194 is above the median of 100 across 690 observational studies indexed under Brain Injuries.
Browse Brain Injuries studies →Banyan Biomarkers, Inc is the lead sponsor of 9 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Subjects eligible for study participation will be over the age of 18 with a standard of care head CT result from the local neuroradiologist and be able to undergo an initial blood draw within 6 hours of head injury. Subjects who will be permitted into the study include those who will meet all the inclusion criteria and will have none of the exclusion criteria. Subjects enrolled into the control cohort will be recruited from the general population.
Head Injured Cohorts Inclusion Criteria:
Head Injured Cohorts Exclusion Criteria:
Control Cohort Inclusion Criteria
Control Cohort Exclusion Criteria
CT negative for acute intracranial lesion with initial blood draw within 4 hours of head injury
Other: Blood draw
CT negative for acute intracranial lesion with initial blood draw within 4-6 hours of head injury
Other: Blood draw
CT positive for acute intracranial lesion with initial blood draw within 4 hours of head injury
Other: Blood draw
CT positive for acute intracranial lesion with initial blood draw within 4-6 hours of head injury
Other: Blood draw
Uninjured control group
Other: Blood draw
Initial draw followed by additional blood draws every 4 hours thereafter, up to 24 hours from the initial blood draw (not to exceed 7 blood draws). Follow up blood draw at Day 7. Control group only undergoes 2 blood draws 4 hours apart on Day 1.
Change in correlation of Banyan UCH-L1/GFAP Detection Assay result with acute intracranial lesions on head CT scan
Time frame: initial, 4hr, 8hr,12hr,16hr, 20hr, 24hr, Day 7
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Banyan Biomarkers, Inc